MedTrace Logo

Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia

NCT00283179 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2008-05-15

No results posted yet for this study

Summary

To evaluate the efficacy, safety and tolerability of aripiprazole in the treatment of acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder with risperidone as an active control.

Conditions

Interventions

DRUG

Aripiprazole

DRUG

Risperidone

Sponsors & Collaborators

  • Taiwan Otsuka Pharm. Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Tzung-Jeng Hwang, M.D., M.P.H. · National Taiwan University Hospital

  • Hung-Yu Chan, M.D. · Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan

  • Wei-Wen Lin, M.D., Ph.D. · Tri-Service General Hospital

  • Shih-Ku Lin, M.D. · Taipei City Psychiatric Center

  • Tung-Ping T. Su, M.D. · Taipei Veterans General Hospital, Taiwan

  • Hai-Gwo Hwu, M.D. · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Completion
2004-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283179 on ClinicalTrials.gov